Quick Answer
Shuttle Pharmaceuticals Holdings, Inc. reported Cash and Equivalents of $334.0 thousand for fiscal year 2025.
Shuttle Pharmaceuticals Holdings, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $334.0K | -82.6% |
| 2024 | $1.92M | -25.5% |
| 2023 | $2.58M | -69.4% |
| 2022 | $8.42M | +1567.6% |
| 2021 | $504.7K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.09M | +1237.1% | -56.5% |
| June 30, 2025 | $4.82M | +592.6% | +6.8% |
| March 31, 2025 | $4.51M | +222.6% | +135.0% |
| December 31, 2024 | $1.92M | -25.5% | +1125.7% |
| September 30, 2024 | $156.7K | -96.0% | -77.5% |
| June 30, 2024 | $695.6K | -87.2% | -50.3% |
| March 31, 2024 | $1.40M | -80.5% | -45.7% |
| December 31, 2023 | $2.58M | -69.4% | -33.7% |
- Shuttle Pharmaceuticals Holdings, Inc. showed a decrease of -82.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, Shuttle Pharmaceuticals Holdings, Inc.’s cash and equivalents has declined by 33.8% (from $504.7 thousand to $334.0 thousand).
- The most recent figure is from Shuttle Pharmaceuticals Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: